| abstract |
The present disclosure is directed to methods of administering thyroid hormone receptor agonists. The present disclosure relates to obesity, hyperlipidemia, hypercholesterolemia, diabetes, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, atherosclerosis, cardiovascular disease, hypothyroidism, and related disorders In ameliorating or healing, a method is provided that reduces or eliminates thyroid-related and thyroid-axis-related side effects while maintaining the activity of a given thyroid receptor agonist. |